Hence, we speculate that to fully explore the potential of intermediate monocytes or CXCR3+ Th17 cells to drive bone loss in RA, future longitudinal studies in patient groups with longer disease duration and more progressed bone loss are required. Here, CXCR3 is linked to rheumatoid arthritis.